AGILE THRPE

NASDAQ: AGRX (Agile Therapeutics, Inc.)

Last update: 10 Nov, 9:19PM

4.01

0.32 (8.67%)

Previous Close 3.69
Open 3.60
Volume 117,859
Avg. Volume (3M) 27,009
Market Cap 3,965,790
Price / Earnings (TTM) 0.044
Price / Sales 0.310
Price / Book 1.78
52 Weeks Range
3.36 (-16%) — 141.00 (3416%)
Earnings Date 9 Aug 2023 - 14 Aug 2023
Profit Margin -73.52%
Operating Margin (TTM) -49.25%
Diluted EPS (TTM) -1.70
Quarterly Revenue Growth (YOY) 1.30%
Current Ratio (MRQ) 0.550
Return on Assets (TTM) -61.55%

AIStockmoo Score

-3.3
Weak profitability. Thin short-term liquidity. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Earnings Trend info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Far below its 52-week high. info
Near its medium-term trend line. info
From our AI technical analysis of the chart. info NA
Technical Setup info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Insider Activity info NA
Institutional Flow info NA
Short Interest info NA
Market environment cautious. info
Sector outperforming the market.
The pillars agree, so the score is strengthened.
Price is high against its 52-week average. Down over 5 years. info
No clear trend across the short, medium and long term. info
Levels trending up. info
Final Score -3.33
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Agile Therapeutics, Inc. - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
AGRX 4 M - 0.044 1.78 -3.3
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
TKNO 480 M - - - 0.8
AQST 435 M - - - -1.7

Select this tab to load the latest available analysis.

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 9.70%
% Held by Institutions 16.02%

No data within this time range.

No data within this time range.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria